About Genedrive

Genedrive develops molecular diagnostic systems for point of care pharmacogenetic testing. The platform reveals how individual genetics affect drug efficacy, enabling clinicians to tailor antibiotic and antiplatelet treatments. This precision reduces adverse reactions and improves outcomes in emergency and critical care settings. The flagship MT-RNR1 and CYP2C19 ID Kits, developed with NHS partners, run on the Genedrive System. The MT-RNR1 test prevents aminoglycoside induced deafness in neonates. The CYP2C19 test optimises antiplatelet therapy for stroke patients. Point of care testing brings laboratory grade genetic analysis to the bedside within the critical treatment window.